Horiko Capital Management LLC Sells 1,122 Shares of McKesson Corporation $MCK

Horiko Capital Management LLC decreased its position in shares of McKesson Corporation (NYSE:MCK) by 2.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,281 shares of the company’s stock after selling 1,122 shares during the period. McKesson accounts for about 8.4% of Horiko Capital Management LLC’s investment portfolio, making the stock its 6th largest holding. Horiko Capital Management LLC’s holdings in McKesson were worth $35,636,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of McKesson by 2.0% during the 2nd quarter. Vanguard Group Inc. now owns 12,072,090 shares of the company’s stock valued at $8,846,186,000 after purchasing an additional 232,286 shares during the period. Franklin Resources Inc. raised its stake in shares of McKesson by 3.5% in the 3rd quarter. Franklin Resources Inc. now owns 2,681,321 shares of the company’s stock worth $2,071,428,000 after buying an additional 90,948 shares in the last quarter. Alliancebernstein L.P. lifted its holdings in shares of McKesson by 5.6% in the third quarter. Alliancebernstein L.P. now owns 2,394,699 shares of the company’s stock valued at $1,850,001,000 after buying an additional 126,684 shares during the period. Norges Bank bought a new position in McKesson during the second quarter valued at about $1,346,661,000. Finally, Boston Partners boosted its stake in McKesson by 6.7% during the third quarter. Boston Partners now owns 1,330,953 shares of the company’s stock valued at $1,027,569,000 after buying an additional 83,357 shares in the last quarter. 85.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

MCK has been the topic of several research reports. TD Cowen boosted their price target on shares of McKesson from $1,000.00 to $1,012.00 and gave the stock a “buy” rating in a research report on Thursday, February 5th. Mizuho raised their price objective on shares of McKesson from $880.00 to $885.00 and gave the company a “neutral” rating in a research report on Thursday, February 5th. Weiss Ratings cut shares of McKesson from a “buy (a-)” rating to a “buy (b+)” rating in a research note on Thursday, February 5th. Zacks Research downgraded shares of McKesson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 25th. Finally, Raymond James Financial set a $970.00 target price on shares of McKesson in a research note on Thursday, March 5th. Thirteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $960.93.

McKesson Stock Down 0.3%

Shares of McKesson stock opened at $941.51 on Monday. McKesson Corporation has a 12-month low of $637.00 and a 12-month high of $999.00. The firm has a market capitalization of $115.33 billion, a PE ratio of 27.08, a price-to-earnings-growth ratio of 1.51 and a beta of 0.38. The stock’s fifty day moving average is $893.90 and its 200-day moving average is $826.35.

McKesson (NYSE:MCK) last released its quarterly earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share for the quarter, beating analysts’ consensus estimates of $9.19 by $0.15. The business had revenue of $106.16 billion during the quarter, compared to analyst estimates of $105.98 billion. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.McKesson’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same quarter last year, the company posted $8.03 EPS. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. Analysts expect that McKesson Corporation will post 32.77 EPS for the current year.

McKesson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Stockholders of record on Monday, March 2nd will be given a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, March 2nd. McKesson’s dividend payout ratio (DPR) is 9.43%.

Insider Buying and Selling at McKesson

In other McKesson news, EVP Leann B. Smith sold 190 shares of McKesson stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $945.00, for a total transaction of $179,550.00. Following the transaction, the executive vice president directly owned 2,989 shares in the company, valued at approximately $2,824,605. The trade was a 5.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Michele Lau sold 2,725 shares of the stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $990.00, for a total value of $2,697,750.00. Following the completion of the sale, the executive vice president owned 3,247 shares of the company’s stock, valued at $3,214,530. The trade was a 45.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 3,868 shares of company stock valued at $3,743,820 over the last three months. 0.08% of the stock is owned by insiders.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.